[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Glyance\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100631068",false,"NCT07495865","Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2","A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.","Inclusion Criteria:\n\n* Men or women of any race, 18 years of age or older.\n* Able to read, understand and sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women (contraindications as per IFU).\n* Having received prior dermal filler injections in the six months preceding the study.\n* Previously treated with semi-permanent or permanent filler in the intended injection area.\n* Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.\n* Known hypersensitivity to lidocaine and\u002For lidocaine HCl or hyaluronic acid.\n* Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.\n* Undergoing or planning to undergo peeling treatment or laser-\u002Fultrasound-based treatment within 3 weeks before or after injection.\n* Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.\n* Subject, who has a condition or is in Fuse",true,"ALL","18 Years",{"count":19,"type":20},87,"ESTIMATED","OBSERVATIONAL","Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.",[24],"Wrinkles",[24],"RECRUITING","2026-05-26",{"date":29,"type":30},"2026-05-28","ACTUAL",{"date":32,"type":30},"2026-02-08",{"date":34,"type":20},"2027-03-12",{"name":36,"class":37},"Glyance","INDUSTRY",""]